176 related articles for article (PubMed ID: 1546140)
1. MAOIs to RIMAs in anaesthesia--a literature review.
Hill S; Yau K; Whitwam J
Psychopharmacology (Berl); 1992; 106 Suppl():S43-5. PubMed ID: 1546140
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase inhibitors. An update on drug interactions.
Livingston MG; Livingston HM
Drug Saf; 1996 Apr; 14(4):219-27. PubMed ID: 8713690
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase inhibitors and anesthesia: an updated literature review.
Blom-Peters L; Lamy M
Acta Anaesthesiol Belg; 1993; 44(2):57-60. PubMed ID: 8237297
[TBL] [Abstract][Full Text] [Related]
4. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
Tiller JW; Maguire KP; Davies BM
Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
6. Current place of monoamine oxidase inhibitors in the treatment of depression.
Shulman KI; Herrmann N; Walker SE
CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
Lotufo-Neto F; Trivedi M; Thase ME
Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
[TBL] [Abstract][Full Text] [Related]
8. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
Da Prada M; Zürcher G; Wüthrich I; Haefely WE
J Neural Transm Suppl; 1988; 26():31-56. PubMed ID: 3283290
[TBL] [Abstract][Full Text] [Related]
9. Serotonin syndrome and drug combinations: focus on MAOI and RIMA.
Hilton SE; Maradit H; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1997; 247(3):113-9. PubMed ID: 9224903
[TBL] [Abstract][Full Text] [Related]
10. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
12. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
Korn A; Eichler HG; Fischbach R; Gasic S
Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
[TBL] [Abstract][Full Text] [Related]
13. RIMA--a new concept in the treatment of depression with moclobemide.
Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
[TBL] [Abstract][Full Text] [Related]
14. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
Liebowitz MR; Hollander E; Schneier F; Campeas R; Welkowitz L; Hatterer J; Fallon B
Acta Psychiatr Scand Suppl; 1990; 360():29-34. PubMed ID: 2248064
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions with reversible monoamine oxidase-A inhibitors.
Callingham BA
Clin Neuropharmacol; 1993; 16 Suppl 2():S42-50. PubMed ID: 8313396
[TBL] [Abstract][Full Text] [Related]
16. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
17. Interaction between moclobemide and oral tyramine in depressed patients.
Burgess CD; Mellsop GW
Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
[TBL] [Abstract][Full Text] [Related]
18. Tyramine and new monoamine oxidase inhibitor drugs.
Simpson GM; de Leon J
Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
20. Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.
Lecrubier Y
Drug Saf; 1994 Apr; 10(4):292-300. PubMed ID: 8018301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
